Abilita Bio has established several global collaborations around the Enabled Membrane Proteins (EMP™) platform, including a multi-target proof of concept agreement with an undisclosed global pharmaceutical company.
WORKING WITH ABILITA BIO
The EMP™ platform facilitates the discovery and development of drugs targeting membrane proteins, including GPCRs and ion channels.
Abilita Bio is seeking corporate relationships under the following models:
Collaborative/risk-sharing development programs
Discovery-based licenses for single or multiple targets
To learn more about our collaboration models please contact us.